Aldeyra Therapeutics, Inc. ALDX
We take great care to ensure that the data presented and summarized in this overview for Aldeyra Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALDX
View all-
Perceptive Advisors LLC New York, NY9.28MShares$19.3 Million2.23% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$11.4 Million21.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.72MShares$7.73 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$7.53 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT1.75MShares$3.64 Million2.26% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.23MShares$2.57 Million0.18% of portfolio
-
Geode Capital Management, LLC Boston, MA1.14MShares$2.37 Million0.0% of portfolio
-
State Street Corp Boston, MA1.02MShares$2.12 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY779KShares$1.62 Million0.51% of portfolio
-
Eagle Asset Management Inc St Petersburg, FL710KShares$1.48 Million0.02% of portfolio
Latest Institutional Activity in ALDX
Top Purchases
Top Sells
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Insider Transactions at ALDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 03
2025
|
Perceptive Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,400,000
-36.65%
|
$3,400,000
$1.42 P/Share
|
|
Aug 12
2024
|
Bruce Greenberg |
SELL
Open market or private sale
|
Direct |
10,834
-7.9%
|
$43,336
$4.74 P/Share
|
|
Aug 12
2024
|
Stephen Machatha Chief Development Officer |
SELL
Open market or private sale
|
Direct |
16,041
-6.35%
|
$64,164
$4.74 P/Share
|
|
Apr 05
2024
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
37,712
+0.4%
|
$150,848
$4.74 P/Share
|
|
Apr 04
2024
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
140,281
+1.5%
|
$561,124
$4.67 P/Share
|
|
Apr 03
2024
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
309,847
+3.29%
|
$1,239,388
$4.09 P/Share
|
|
Apr 02
2024
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
186,051
+2.07%
|
$558,153
$3.44 P/Share
|
|
Apr 01
2024
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,374
+0.1%
|
$25,122
$3.25 P/Share
|
|
Mar 12
2024
|
Todd C Brady President and CEO |
SELL
Open market or private sale
|
Direct |
85,324
-5.48%
|
$255,972
$3.05 P/Share
|
|
Mar 12
2024
|
Stephen Machatha Chief Development Officer |
SELL
Open market or private sale
|
Direct |
11,537
-4.52%
|
$34,611
$3.16 P/Share
|
|
Mar 11
2024
|
Bruce Greenberg |
SELL
Open market or private sale
|
Direct |
13,201
-9.86%
|
$39,603
$3.41 P/Share
|
|
Mar 11
2024
|
Todd C Brady President and CEO |
SELL
Open market or private sale
|
Direct |
97,914
-5.92%
|
$293,742
$3.27 P/Share
|
|
Mar 11
2024
|
Stephen Machatha Chief Development Officer |
SELL
Open market or private sale
|
Direct |
18,231
-6.67%
|
$54,693
$3.41 P/Share
|
|
Oct 18
2023
|
Perceptive Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
306,499
-3.44%
|
$306,499
$1.74 P/Share
|
|
Oct 16
2023
|
Perceptive Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,450,000
-21.59%
|
$2,450,000
$1.6 P/Share
|
|
Sep 07
2023
|
Todd C Brady President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
73,807
-4.27%
|
$516,649
$7.22 P/Share
|
|
Sep 07
2023
|
Todd C Brady President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
273,058
+5.02%
|
$0
$0.55 P/Share
|
|
Sep 07
2023
|
Gary M. Phillips |
BUY
Exercise of conversion of derivative security
|
Direct |
5,437
+26.85%
|
$0
$0.55 P/Share
|
|
Aug 22
2023
|
Neal Walker |
BUY
Exercise of conversion of derivative security
|
Direct |
9,604
+37.72%
|
$0
$0.55 P/Share
|
|
Jun 27
2023
|
Ben Bronstein |
BUY
Exercise of conversion of derivative security
|
Direct |
9,604
+25.37%
|
$0
$0.55 P/Share
|
Last 12 Months Summary
| Open market or private sale | 3.43M shares |
|---|